Background: It has been known that Brain-Derived Neurotrophic Factor (BDNF) is involved in neural survival and long term memory (LTM). Here we hypothesized that BDNF as a potent neurotrophic factor might modulate amnestic effect induced by morphine. Objectives: The aim of this study was to examine whether infusion of exogenous BDNF in the CA1 regions of the dorsal hippocampi could ameliorate memory impairment induced by morphine. Materials and Methods: Forty rats were divided into 5 groups for dose response study of morphine (2.5, 5, 7.5 and 10 mg/kg morphine, and saline, intraperitoneal) on memory retention. For second part of the experiment 24 animals were divided into three groups: (morphine +BDNF, morphine + saline and saline + saline). Two weeks after stereotaxic surgery, animals received 0.5 μl bilateral infusion of either saline or BDNF (5 µg/rat) intrahippocampally, 30 minutes before morphine treatment (7.5 mg/kg, i.p.).
Introduction
orphine has been widely used in pain treatment, but its strong dependency potential is a serious challenge to its clinical usage. It is reported that opioid peptides, especially morphine influence on the processes of learning and causes memory impairment. Impairment of memory has been reported after both chronic and acute morphine administration (1) (2) (3) (4) . Preor post-training administration of morphine 13 impairs specifically performance in the passive avoidance task (3, 5) . Memory is critically depended on the hippocampus region, and can be divided into short-term and long-term forms (6, 7) . Consolidation of short term (STM) to longterm (LTM) memory takes place immediately following the training experience (8, 9) . This critical period is influenced by different neurotransmitters including glutamate, acetylcholine and dopamine (10) (11) (12) (13) . Moreover, LTM strongly depends on protein synthesis cascades and neurotropic factors particularly BDNF (14) (15) (16) . According to the previous reports hippocampal BDNF appears to be necessary for LTM formation in the different discrete periods, immediately after, 1.4 hour and 3.6 hours after training (17, 18) . Although many studies proposed that BDNF is a key molecule mediating persistence and maintenance LTM, it is still unclear whether BDNF pretreatment is capable of ameliorating memory impairment. This study was conducted to answer to this question.
Materials and Methods

Animals:
Sixty four male wistar rats weighing 200-250g were used in this study. They had free access to food and water, and kept at 24 
Surgery:
The animals were anaesthetized via the intraperitoneal (i.p.) injection of ketamine and xylazine (100 and 10 mg/kg, respectively), and fixed in the flat -skull position using stereotaxic apparatus (David Kopf Instruments, USA).The rats' scalp were cut, a small craniotomy was drilled and cannulas (22-gauge diameter) were bilaterally implanted into the CA1 region of the hippocampus at coordinates: AP − 3mm, L ± 2mm and V − 2.8mm (19) .
Micro infusions:
Morphine sulphate (Darupakhsh, Iran) and human recombinant BDNF (R&D, USA) were dissolved in sterile 0.9% saline. First, animals were divided into five groups (saline, morphine 2.5, 5, 7.5 and 10 mg/kg.) for dose response study of morphine. Secondly, 24 rats were divided into three experimental groups (morphine + BDNF, morphine + saline and saline + saline, n = 8 each) and underwent stereotaxic surgery. Two weeks later, animals received a 0.5 μl bilateral infusion of saline or BDNF (2.5µg/0.5μl/side) intra -hippocampally 30 minutes before morphine treatment (7.5 mg/kg, i.p.).
Inhibitory avoidance apparatus:
The apparatus consisted of two equal size of compartments, one light and one dark (20×20×30 cm high), connecting via a guillotine door (7×9 cm). The floor of the dark compartment was made of stainless steel rods (2.5 mm in diameter) with a distance of 1 cm.
For the acquisition trial, rat was placed in the light compartment and the door between the two compartments was opened 20 seconds later. When the rat entered the dark compartment, the door closed and an electric foot shock (1 mA, 50 Hz, 5 seconds) was delivered through the grid floor. For the retention trial, the rat was again placed in the light compartment 1.5 and 24 hours following the acquisition trial. The latency time (seconds) for entering the dark compartment was recorded. Upon completion of the inhibitory avoidance test, each rat was deeply anesthetized and 1 ml of a 4% methylene-blue solution was bilaterally infused through the cannula into the CA1 (0.5ml/side). The animals were decapitated and the brains were removed and placed in formaldehyde for two days (10%). Then, the brains were sliced and the injection site was verified according to the 
Data analysis:
Each value represents the mean ± standard error of the mean (S.E.M.). After assaying the normality of data with Kolmogorov -Smirnov test, comparison of data among groups was performed using one-way analysis of variance with Tukey's post-test , when the p-values was < 0.05, the difference was considered to be significant. Calculations were performed using the SPSS statistical package version 19.
Results
During the training trial, there was no significant difference among groups (p > 0.05, one way ANOVA). Systemic post-training administration of morphine (7.5 and 10 mg/kg) immediately after the training significantly decreased latency to enter to the dark compartment compared to the control receiving saline (p < 0.01; Diagram 1). Following infusion of BDNF or saline, a 30 minutes wait-time and then an i.p. injection of morphine or saline, the rats performed the acquisition trial of the inhibitory avoidance test. Memory was assessed during the retention trial by measuring step-through latency in the passive avoidance task observed 1.5 and 24 hours after the acquisition trial (Diagram 2).
Diagram 2.
The effect of acute BDNF pretreatment on memory consolidation prior to morphine injection. The latencies for the rat (n = 8 per group) to enter to the dark room 1.5 h and 24 h after the training were expressed as mean ± S.E.M. *p < 0.01 , ***p < 0.001 compared to morphine.
There was a strong significant group effect (F(2, 21) = 37; p = 0.001, one way ANOVA) showing that the group receiving BDNF 30 minutes prior to morphine administration (BDNF + morphine) took longer to enter the dark chamber compared to either control group, saline + morphine or saline + saline. 
Discussion
In the current study, we showed that administration of morphine immediately after training impairs memory retention in the inhibitory avoidance test. Additionally, exogenous BDNF infusion into the hippocampal CA1 region, 30 minutes before morphine administration, ameliorated the morphine-induced memory impairment. The impairment of memory induced by morphine is consistent with previous studies (3, 20, 21) . Based on the immediate posttraining administration of morphine and its short half-life in the brain (approximately 1 hour), it is likely that morphine is affecting the early phase of memory consolidation (22) . Opioids produce their principal effects on memory by binding to at least three different types of receptors: μ, δ and κ opioid receptors (3). All opioid receptor subtypes inhibit adenylyl cyclase and Ca 2+ channels and stimulate K + channels. These effects are required for morphine-induced amnesia in the passive avoidance test (23) . Alternately, neuropharmacological studies have revealed that activation of opioid receptors may decrease the function of the cholinergic system (24) (25) (26) . However, one cannot exclude the possibility that morphine interferes with other neurotransmitter systems, such as adrenergic or dopaminergic, to induce amnesia (27, 28) . Interestingly, we also showed that infusion of BDNF into the dorsal hippocampus 30 minutes before training was sufficient to prevent the amnestic effect of morphine as well as enhance memory consolidation compared to the saline control group. To our knowledge, this study was the first to demonstrate that BDNF attenuates morphineinduced memory impairment. Animal and human studies suggest that hippocampal BDNF plays a major role in memory by promoting neural plasticity (29, 30) . Additionally, BDNF is required for the consolidation of short-term and long-term memory, especially in glutamatergic and GABAergic synapses (29, (31) (32) (33) . Previous studies report an increase in BDNF mRNA in the dentate gyrus of the hippocampus following the acquisition trial (17, 34) . Conversely, Alonso et al. (2002) showed that infusion of an anti-BDNF antibody impaired LTM, when given 15 minutes before or 1 and 4 hours after training (17) . Our results were in agreement with the Johnston et al. study showing that injection of recombinant BDNF before training enhanced memory recall in day old chicks (35) . Our findings confirmed that 30 minutes before the induction of amnesia was a sensitive time window which was critical for LTM formation, so it is more likely to relate this result to acute effects of BDNF on synaptic transmission, rather than protein synthesis due to inadequate time. Binding of BDNF to tropomyosin receptor kinase B (TrkB) triggers a number of intra-cellular signalling pathways from long lasting effects to enhancing early long term potentiation (LTP) and phosphorylation of synaptic proteins (36) (37) (38) (39) . Rapid Ca 2+ influx through NMDA-type glutamate receptors and subsequent protein phosphorylation events modify pre-existing synapses and trigger early LTP, an important mechanism mediating memory formation (40, 41) . A recent surprising study revealed suppressive effect of BDNF as a negative modulator on morphine reward (42) . Some of the neurotransmitters regulate BDNF synthesis, and in turn they are regulated by BDNF. For example BDNF modulates acetylcholine, dopamine, and glutamate release in the hippocampus, depolarizes neurons and interferes in Ca signaling (43) (44) (45) (46) (47) (48) (49) (50) (51) . The significance of these reciprocal regulations was intriguing and could represent a novel framework into the molecular basis of morphine-induced amnesia.
For future studies we propose administration of antibody against BDNF and also different doses of BDNF prior to morphine injection.
Conclusion
The present study shows that morphine impairs the consolidation phase of long-term recognition memory, possibly by preventing a learning-induced increase in BDNF levels in the hippocampus. This study suggests that intra-hippocampal infusion of BDNF prevents the deficit in memory consolidation caused by morphine.
